Methoxy polyethylene glycol-epoetin beta Completed Phase 4 Trials for Anemia Treatment

Back to Methoxy polyethylene glycol-epoetin beta
IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01342640A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
NCT01191983A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
NCT01156363A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
NCT00922116A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis
NCT00922610A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients
NCT00737711A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
NCT00737464A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
NCT00642668A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia